Medpedia

Barry H Ginsberg MD, PhD's Answers

  • Inhaled insulin used to have agreat strategy: find the patients with type 2 diabetes not doing well on oral agents and switch them to inhaled insulin before they were able to overcome their fear of i njection...
  • I actually disagree with Dr Mahboob. I think it is unlikely it will ever become a product.
  • Not currently. There is a company using it in clinical trials. The problems with nasal insulin included a lack of bioavailability ( patients needed to take 12 times as much insulin) and nasal irrita tion...
  • Classically, the thumb was not considered a good site, but the reasons have to do with ancient blood glucose testing. Back when lancets were 21 gauge and blood drop size was 10-15 uL, there was subst antial...
  • Both Januvia and Byetta work on the Incretin pathway, Byetta acts like GLP-1 and Januvia extends the life of your natural GLP-1. Byetta needs to be injected twice daily and needs to be kept cold, alt hough...
  • There are many kinds of diabetic neuropathy: peripheral neuropathy (with a variety of manifestations, but mostly loss of sensation in the hands and feet, sometimes with pain), autonomic neuropathy, di abetic...
  • The dietary requirements are different for type 1 and type 2 diabetes. In type 2 the goal is usually weight and fat reduction to lower insulin resistance and restriction of glycemic load, that is not overloading...
Editor Directory - browse by last initial
ABCDEFGHIJKLMNOPQRSTUVWXYZ
Professional Directory - browse by last initial
ABCDEFGHIJKLMNOPQRSTUVWXYZ
Cancel